Adlai Nortye combines explosive revenue growth with severe cash burn, an unreliable analyst price target, and a business-quality score below the investment floor, leaving the growth narrative overshadowed by financial and data-quality concerns.
Thesis pillars
- Explosive Revenue Growth—
- Severe Cash Burn—
- Unreliable Analyst Target Data—
- +2 more pillars — see the Why tab for full reasoning
Adlai Nortye Ltd. (ANL) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $11.35: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination... Read more
Sell if holding. Engine safety override at $11.35: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Score 6.6/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-16Recent Developments — Adlai Nortye Ltd.
Latest news
- NEWS Adlai Nortye Doses First Patient In The Intermittent Weekly Dosing Arm In Its Ongoing Phase 1 Clinical Trial Of AN9025, — benzinga Jul 16, 2026 positive
- NEWS Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower — benzinga Jun 30, 2026 neutral
Generated 2026-07-16T22:57:05Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.35: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Prior stop was $10.56. Score 6.6/10, moderate confidence.
Take-profit target: $24.88 (+119.2% upside). Prior stop was $10.56. Stop-loss: $10.56.
Quality below floor (3.3 < 4.0).
Adlai Nortye Ltd. trades at a P/E of N/A (forward -28.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
10 analysts cover ANL with a consensus score of 4.2/5. Average price target: $29.
What does Adlai Nortye Ltd. do?Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops...
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.